382 related articles for article (PubMed ID: 37691932)
1. Cancer immunotherapies: advances and bottlenecks.
Rui R; Zhou L; He S
Front Immunol; 2023; 14():1212476. PubMed ID: 37691932
[TBL] [Abstract][Full Text] [Related]
2. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications.
Zhang Y; Zhang Z
Cell Mol Immunol; 2020 Aug; 17(8):807-821. PubMed ID: 32612154
[TBL] [Abstract][Full Text] [Related]
3. Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression.
Saleh R; Elkord E
Semin Cancer Biol; 2020 Oct; 65():13-27. PubMed ID: 31362073
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy and tumor microenvironment.
Tang H; Qiao J; Fu YX
Cancer Lett; 2016 Jan; 370(1):85-90. PubMed ID: 26477683
[TBL] [Abstract][Full Text] [Related]
5. Impact of tumor microenvironment on adoptive T cell transfer activity.
Martín-Otal C; Navarro F; Casares N; Lasarte-Cía A; Sánchez-Moreno I; Hervás-Stubbs S; Lozano T; Lasarte JJ
Int Rev Cell Mol Biol; 2022; 370():1-31. PubMed ID: 35798502
[TBL] [Abstract][Full Text] [Related]
6. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
[TBL] [Abstract][Full Text] [Related]
7. Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy.
Liu X; Si F; Bagley D; Ma F; Zhang Y; Tao Y; Shaw E; Peng G
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36192086
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
Sasidharan Nair V; Elkord E
Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
[TBL] [Abstract][Full Text] [Related]
9. Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape.
Osipov A; Saung MT; Zheng L; Murphy AG
J Immunother Cancer; 2019 Aug; 7(1):224. PubMed ID: 31439034
[TBL] [Abstract][Full Text] [Related]
10. Cancer immunotherapy: accomplishments to date and future promise.
Helmy KY; Patel SA; Nahas GR; Rameshwar P
Ther Deliv; 2013 Oct; 4(10):1307-20. PubMed ID: 24116914
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in ovarian cancer.
Odunsi K
Ann Oncol; 2017 Nov; 28(suppl_8):viii1-viii7. PubMed ID: 29232467
[TBL] [Abstract][Full Text] [Related]
12. An Ex Vivo 3D Tumor Microenvironment-Mimicry Culture to Study TAM Modulation of Cancer Immunotherapy.
Li YR; Yu Y; Kramer A; Hon R; Wilson M; Brown J; Yang L
Cells; 2022 May; 11(9):. PubMed ID: 35563889
[TBL] [Abstract][Full Text] [Related]
13. Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions.
Granhøj JS; Witness Præst Jensen A; Presti M; Met Ö; Svane IM; Donia M
Expert Opin Biol Ther; 2022 May; 22(5):627-641. PubMed ID: 35414331
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
Russell L; Peng KW; Russell SJ; Diaz RM
BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
[TBL] [Abstract][Full Text] [Related]
15. Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors.
Balta E; Wabnitz GH; Samstag Y
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072260
[TBL] [Abstract][Full Text] [Related]
16. The State of Immunotherapy in Hepatobiliary Cancers.
Ilyas FZ; Beane JD; Pawlik TM
Cells; 2021 Aug; 10(8):. PubMed ID: 34440865
[TBL] [Abstract][Full Text] [Related]
17. Adoptive tumor infiltrating lymphocyte transfer as personalized immunotherapy.
Diaz-Cano I; Paz-Ares L; Otano I
Int Rev Cell Mol Biol; 2022; 370():163-192. PubMed ID: 35798505
[TBL] [Abstract][Full Text] [Related]
18. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
19. Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.
Vigano S; Alatzoglou D; Irving M; Ménétrier-Caux C; Caux C; Romero P; Coukos G
Front Immunol; 2019; 10():925. PubMed ID: 31244820
[TBL] [Abstract][Full Text] [Related]
20. Optimising NK cell metabolism to increase the efficacy of cancer immunotherapy.
Choi C; Finlay DK
Stem Cell Res Ther; 2021 Jun; 12(1):320. PubMed ID: 34090499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]